Short Interest in Sera Prognostics, Inc. (NASDAQ:SERA) Decreases By 34.0%

Sera Prognostics, Inc. (NASDAQ:SERA) was the recipient of a large drop in short interest in the month of August. As of August 15th, there was short interest totaling 817,900 shares, adropof34.0% from the July 31st total of 1,240,000 shares. Based on an average daily volume of 370,900 shares, the short-interest ratio is presently 2.2 days. Approximately3.3% of the company’s shares are sold short. Approximately3.3% of the company’s shares are sold short. Based on an average daily volume of 370,900 shares, the short-interest ratio is presently 2.2 days.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Sera Prognostics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th.

Institutional Trading of Sera Prognostics

A number of hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in shares of Sera Prognostics in the 4th quarter worth about $28,000. XTX Topco Ltd acquired a new position in shares of Sera Prognostics during the first quarter valued at $39,000. Abel Hall LLC acquired a new position in shares of Sera Prognostics during the second quarter valued at $31,000. Price T Rowe Associates Inc. MD bought a new position in Sera Prognostics during the fourth quarter valued at about $93,000. Finally, Gotham Asset Management LLC acquired a new position in shares of Sera Prognostics in the 4th quarter valued at $96,000. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Trading Down 1.5%

Shares of SERA stock opened at $3.29 on Monday. The stock has a market cap of $123.93 million, a price-to-earnings ratio of -3.87 and a beta of 1.00. The company’s 50-day moving average price is $2.76 and its 200-day moving average price is $2.88. Sera Prognostics has a twelve month low of $1.37 and a twelve month high of $9.13.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%. As a group, equities research analysts predict that Sera Prognostics will post -0.96 EPS for the current year.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.